ENSAYOS CLÍNICOS GLÁNDULAS SALIVALES ABIERTOS A RECLUTAMIENTO (Actualizado Junio 2020)

FUENTE de la INFORMACIÓN OBTENIDA: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

EudraCT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD	COMENTS
2015-002067-41	2628067	**3475-158**	Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158)	Fase II	**Tumores sólidos avanzados (Thyroid Carcinoma Salivary Gland Carcinoma)**	RECLUTING	**Pembrolizumab (i.v)**	H.U.Vall d´Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid)	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Oncologia Medica	N= 1295 Single Group Assignment
2015-003385-84	2568267	**RXDX-101-02**	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid **Tumors** That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Fase II	**Salivary Gland Cancers** & Adult Solid Tumor (Papillary thyroid cancer and H&N cancer)	RECLUTING	**Entrectinib**	H.U.Vall d´Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.12 Octubre (Madrid) H.C.U.San Carlos (Madrid) Start_ClOClara Campal (Madrid) H.U.V.Victoria (Malaga) H.U.V.Rocio (Sevilla)	Hoffma-La Roche / Ignyta,Inc	Oncologia Medica	N = 300
2015-003582-28	2576431	**LOXO-TRX-15002(NAVEGATE)**	A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects With NTRK Fusion-positive **Tumors**	Phase II	Experimental: **Arm 5_Salivary,** Patients with solid salivary tumors harboring NTRK fusions	RECLUTING	**Larotrectinib** will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles. **BAY2757556 (Larotrectinib)** Other Name:LOXO-101	H.U.San Chinarro(Madrid) F.Jimenez Diaz (Madrid)	Bayer	Oncologia_Medica	N= 203 **12 years and older**